ANI Pharmaceuticals, Inc.
ANIP
$82.09
-$0.59-0.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.87% | 38.68% | 30.26% | 26.20% | 23.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.87% | 38.68% | 30.26% | 26.20% | 23.60% |
| Cost of Revenue | 47.44% | 43.42% | 42.04% | 37.85% | 33.88% |
| Gross Profit | 49.80% | 35.76% | 23.26% | 19.28% | 17.67% |
| SG&A Expenses | 43.47% | 60.94% | 52.29% | 46.10% | 49.75% |
| Depreciation & Amortization | 51.52% | 41.38% | 27.03% | 13.28% | 2.11% |
| Other Operating Expenses | -- | 2,012.50% | -- | -- | -- |
| Total Operating Expenses | 45.65% | 49.90% | 42.23% | 37.53% | 34.99% |
| Operating Income | 122.12% | -68.26% | -75.46% | -73.83% | -57.69% |
| Income Before Tax | 773.73% | -141.54% | -164.03% | -211.78% | -156.85% |
| Income Tax Expenses | 2,522.09% | -153.42% | -186.88% | -437.60% | -123.91% |
| Earnings from Continuing Operations | 672.15% | -137.80% | -159.21% | -198.63% | -152.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 672.15% | -137.80% | -159.21% | -198.63% | -152.99% |
| EBIT | 122.12% | -68.26% | -75.46% | -73.83% | -57.69% |
| EBITDA | 71.23% | -9.20% | -20.94% | -26.19% | -27.47% |
| EPS Basic | 489.11% | -158.09% | -171.36% | -220.85% | -183.30% |
| Normalized Basic EPS | 363.51% | -109.26% | -122.82% | -124.03% | -80.41% |
| EPS Diluted | 458.77% | -160.92% | -173.56% | -224.65% | -189.91% |
| Normalized Diluted EPS | 358.18% | -110.94% | -123.85% | -125.04% | -80.94% |
| Average Basic Shares Outstanding | 2.78% | 2.60% | 4.16% | 7.37% | 10.88% |
| Average Diluted Shares Outstanding | 4.56% | 2.74% | 3.43% | 6.68% | 10.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.17% | -3.65% | -2.69% | -2.01% | -2.89% |